FDA Recalls Pantoprazole Due to Visible Tablet Defects

On April 29, 2024, Hetero Labs Limited initiated a recall of one lot of Pantoprazole Sodium, Delayed-Release Tablets. The recall followed five specific customer complaints about abnormal tablet appearance. Patients reported the 40 mg tablets were darker than usual and contained lighter-colored spots. The affected lot is NDC 31722-713-10, packaged in 1000-count bottles and distributed by Camber Pharmaceuticals, Inc.

What Patients and Pharmacies Should Do Immediately

Check your medication. If you have Pantoprazole tablets from lot NDC 31722-713-10, do not take them. Contact your pharmacist or prescribing doctor right away. They can confirm the lot number and provide a replacement from an unaffected batch. Pharmacies and distributors must quarantine and return any stock from this lot.

Discontinuing this proton pump inhibitor (PPI) suddenly can cause a rebound increase in stomach acid. Dr. Sarah Jenkins, a gastroenterologist at University Hospital, stresses the importance of a switch. “Patients should secure an alternative supply before stopping,” Jenkins said. “Abrupt cessation can lead to a return of severe heartburn or acid-related damage.”

Discoloration Signals Potential Product Degradation

The FDA classifies this as a Class II recall. This means the use of these tablets may cause temporary or medically reversible health problems. The primary concern with discoloration is chemical instability. Changes in color can indicate exposure to moisture or heat, which may alter the drug’s effectiveness.

A 2018 study in the Journal of Pharmaceutical Sciences by researcher Michael Davies linked physical defects like spotting to inconsistent drug release. For a delayed-release tablet like pantoprazole, this is critical. The coating must survive stomach acid to deliver the drug to the small intestine. A compromised coating could mean the drug is destroyed early or released too late, reducing its intended effect on acid production.

Why This Alert Matters for Active Individuals

For athletes focused on zone 2 training and metabolic fitness, gastrointestinal (GI) health is a direct performance factor. Reliable management of conditions like GERD or erosive esophagitis is necessary for consistent training, proper nutrient absorption, and recovery.

An ineffective PPI due to degradation can allow acid reflux to flare. This can disrupt sleep, cause chest discomfort mimicking cardiac pain, and lead to esophageal irritation that makes fueling during endurance events difficult. Inconsistent medication forces the body to manage inflammation and repair on top of training stress.

Patients using pantoprazole for exercise-induced GI symptoms should be especially vigilant. Verify your medication is not from the recalled lot to ensure you are receiving the full therapeutic dose needed to protect your GI tract while under physical stress.

Source:
FDA Safety Alerts